Cost Effectiveness of Elidel in the Management of Patients with Atopic Dermatitis in Canada

Coyle, Doug; Barbeau, M

doi:10.1007/s10227-004-0111-y

Cited by 11 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PIM is not recommended in these pts (section 8). [85] In general, sensitivity analyses revealed these pharmacoeconomic models to be robust. In these models, the calculated incremental cost per QALY gained are within the generally accepted threshold of these countries.…”

Section: Pharmacoeconomic Considerationsmentioning

confidence: 99%

“…The cost effectiveness of topical pimecrolimus relative to vehicle [85][86][87][88] or to topical tacrolimus [89] in the treatment of pediatric patients with atopic dermatitis has been examined in five pharmacoeconomic analyses. Comparisons between topical pimecrolimus and vehicle were based on the addition of conventional therapy, consisting of regular use of emollients and topical corticosteroids when needed.…”

Section: Pharmacoeconomic Considerationsmentioning

confidence: 99%

“…[85,86] Comparisons between topical pimecrolimus and topical corticosteroids were made between first-line topical corticosteroid therapy and second-line topical pimecrolimus therapy. [89] From a healthcare payer perspective in Canada [85] or the US, [86] topical pimecrolimus plus conventional therapy was cost effective when compared with vehicle plus conventional therapy (table V). PIM is not recommended in these pts (section 8).…”

Section: Pharmacoeconomic Considerationsmentioning

confidence: 99%

“…[89] From a healthcare payer perspective in Canada [85] or the US, [86] topical pimecrolimus plus conventional therapy was cost effective when compared with vehicle plus conventional therapy (table V). However, it should be noted that these are 1-year models [85,86] and are limited in their representation of the longterm treatment requirements of atopic dermatitis. [90] Topical pimecrolimus plus conventional therapy was also cost effective compared with vehicle plus conventional therapy, when analyzed from a Canadian societal perspective (table V).…”

Section: Pharmacoeconomic Considerationsmentioning

confidence: 99%

See 3 more Smart Citations

Topical Pimecrolimus

Yang¹,

Curran²

2009

Pediatric Drugs

View full text Add to dashboard Cite

Topical pimecrolimus 1% cream (Elidel) [hereafter referred to as topical pimecrolimus] is a nonsteroidal alternative in the treatment of pediatric atopic dermatitis. In vehicle-controlled, short-term, continuous-use trials in pediatric patients with mild to moderate atopic dermatitis, topical pimecrolimus was effective in treating disease symptoms. Topical pimecrolimus was effective in preventing disease flares and reducing the need for topical corticosteroids in longer term, intermittent-use trials. In addition, topical pimecrolimus was associated with improvements in the health-related quality of life (HR-QOL) of pediatric patients with atopic dermatitis and their parents. In vehicle-controlled trials, topical pimecrolimus was generally as well tolerated as vehicle. Topical pimecrolimus showed similar efficacy to topical tacrolimus 0.03% ointment (hereafter topical tacrolimus) in a short-term, continuous-use trial and the two agents had a generally similar tolerability profile. Although comparative data between topical pimecrolimus and topical corticosteroids are lacking in pediatric patients, and the long-term tolerability (beyond 1-2 years) of topical pimecrolimus is yet to be established, topical pimecrolimus is a useful agent in the management of pediatric patients with mild to moderate atopic dermatitis who do not achieve satisfactory treatment with other topical pharmacologic treatments, including topical corticosteroids.

show abstract

Section: Pharmacoeconomic Considerationsmentioning

confidence: 99%

Section: Pharmacoeconomic Considerationsmentioning

confidence: 99%

Section: Pharmacoeconomic Considerationsmentioning

confidence: 99%

Section: Pharmacoeconomic Considerationsmentioning

confidence: 99%

See 2 more Smart Citations

Topical Pimecrolimus

Yang¹,

Curran²

2009

Pediatric Drugs

View full text Add to dashboard Cite

show abstract

“…Topical pimecrolimus plus conventional therapy (regular use of emollients and topical corticosteroids as needed) was a costeffective treatment relative to vehicle plus conventional therapy in Canadian [30] and US [31] cost-utility analyses. However, first-line topical corticosteroids dominated second-line topical pimecrolimus following first-line topical corticosteroids in two UK pharmacoeconomic analyses.…”

Section: Pharmacoeconomic Considerationsmentioning

confidence: 99%

Spotlight on Topical Pimecrolimus in Pediatric Atopic Dermatitis†

Yang

Curran

2010

American Journal of Clinical Dermatology

View full text Add to dashboard Cite

Topical pimecrolimus 1% cream (Elidel) [hereafter referred to as topical pimecrolimus] is a nonsteroidal alternative in the treatment of pediatric atopic dermatitis. In vehicle-controlled, short-term, continuous-use trials in pediatric patients with mild to moderate atopic dermatitis, topical pimecrolimus was effective in treating disease symptoms. Topical pimecrolimus was effective in preventing disease flares and reducing the need for topical corticosteroids in longer term, intermittent-use trials. In addition, topical pimecrolimus was associated with improvements in the health-related quality of life of pediatric patients with atopic dermatitis and their parents. In vehicle-controlled trials, topical pimecrolimus was generally as well tolerated as vehicle. Topical pimecrolimus showed similar efficacy to topical tacrolimus 0.03% ointment in a short-term, continuous-use trial and the two agents had a generally similar tolerability profile. Although comparative data between topical pimecrolimus and topical corticosteroids are lacking in pediatric patients, and the long-term tolerability (beyond 1-2 years) of topical pimecrolimus is yet to be established, topical pimecrolimus is a useful agent in the management of pediatric patients with mild to moderate atopic dermatitis who do not achieve satisfactory treatment with other topical pharmacologic treatments, including topical corticosteroids.

show abstract